Genetically modified immune cells take on eight cancer types in early trial
NCT ID NCT04044859
First seen Feb 13, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy drugs. Up to 120 adults with cancers like lung, ovarian, or melanoma are enrolled to check safety and initial signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinica Universitaria de Navarra
Pío, Pamplona, 31008, Spain
-
Duke University Medical Center, Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hospital Clinico de Valencia
Ibanez, Valencia, 46010, Spain
-
Hospital Universitario 12 De Octubre
Madrid, Avenida de Cordoba S/n, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro CIOCC
Madrid, 28050, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Name of Institution: Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Washington University - School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADP-A2M4CD8 T-cells (genetically modified immune cells) alone or with nivolumab or pembrolizumab
What this could lead to
If successful, this could point toward a new treatment option for several hard-to-treat cancers that express MAGE-A4.
What could go wrong
This is an early Phase 1 trial with only 120 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects from the cell therapy and immune checkpoint inhibitors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.